What Is Wegovy Used For? FDA-Approved Uses

The FDA label says: “WEGOVY injection is indicated in combination with a reduced calorie diet and increased physical activity: to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight; to reduce excess body weight and maintain weight reduction long term in:; for the treatment...”

Run it in Rivvi

Which 2027 plans near you dropped or restricted Wegovy?

Tier changes and new prior auth, step therapy or quantity limits, plan by plan.

Free to start. Opens Rivvi, the AI workspace for healthcare teams.

Wegovy, injection, solution

Indications and Usage, quoted from the label by Novo Nordisk Pharmaceutical Industries, LP (NDA215256). Cross-references to other label sections are left out.

WEGOVY injection is indicated in combination with a reduced calorie diet and increased physical activity:
to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight.
to reduce excess body weight and maintain weight reduction long term in:
adults and pediatric patients aged 12 years and older with obesity.
adults with overweight in the presence of at least one weight-related comorbid condition.
for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults. This indication is approved under accelerated approval based on improvement of MASH and fibrosis. Continued approval for this indication may be contingent upon the verification and description of clinical benefit in a confirmatory trial.
WEGOVY tablets are indicated in combination with a reduced calorie diet and increased physical activity:
to reduce the risk of major adverse CV events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight.
to reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight in the presence of at least one weight-related comorbid condition.
Limitations of Use
Concomitant use of WEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.

Source: DailyMed label, set id ee06186f-2aa3-4990-a760-757579d8f77b, version 19, effective June 18, 2026. NDC 0169-4501, one of 8 listings for this product.

Questions

What is Wegovy used for?

The FDA label says: “WEGOVY injection is indicated in combination with a reduced calorie diet and increased physical activity: to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight; to reduce excess body weight and maintain weight reduction long term in:; for the treatment...”

What drug class is Wegovy?

FDA lists semaglutide in the GLP-1 Receptor Agonist established pharmacologic class.

Does this page cover off-label uses or dosing?

No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.

What is Wegovy used for?

Which 2027 plans near you dropped or restricted Wegovy?

Wegovy, injection, solution

Questions

More on Wegovy

Try it on your own data today.